Noviscend Inc, a Canadian medical technology company announced today an agreement with Myriad Genetics, Inc., a leader in genetic testing and precision medicine, for the distribution of its portfolio of genetic tests. Effective immediately, under this new agreement, Noviscend becomes the exclusive distributor of EndoPredict®, MyRisk®, myChoiceCDx®, GeneSight®, Prolaris®, and myRisk® - Hereditary and Single Gene Panel molecular diagnostic tests in Canada.
“For almost 10 years, Myriad Genetics has been active in Canada, making these diagnostic tests accessible to oncologists, gynecologists and pathologists, supporting them in making crucial treatment decisions for their patients”, said Kostas Trakas, CEO at Noviscend Inc. “At Noviscend we look forward to continuing this legacy of service to our customers, but we will also endeavour to expand the diagnostic solutions available for Canadian patients.”
Noviscend would also like to welcome Mark Hammar as Head, Diagnostic Products and Services for Noviscend Inc. As the former country leader for Myriad Genetics Canada, Mark will be a critical leader during this transition period and beyond.